C. Le-laser-au and .. La-chimiothérapie-anticancéreuse, 25 c) Le curetage-électrocoagulation, p.26

P. Caractéristiques-des, 69 a) Caractéristiques démographiques, 69 b) Caractéristiques cliniques et histologiques au diagnostic, p.70

.. Analyse-de-la-réponse-clinique-au-vismodegib, 72 a) Efficacité du traitement, p.74

B. Pinatel and A. Mojallal, Prise en charge diagnostique et th??rapeutique du carcinome cutan?? basocellulaire ??? Analyse des recommandations, Annales de Chirurgie Plastique Esth??tique, vol.57, issue.2, pp.92-105, 2012.
DOI : 10.1016/j.anplas.2012.01.004

C. Rudin and . Vismodegib, Vismodegib, Clinical Cancer Research, vol.18, issue.12, pp.3218-3240, 2012.
DOI : 10.1158/1078-0432.CCR-12-0568

H. Walling, S. Fosko, and P. Geraminejad, Aggressive basal cell carcinoma: Presentation, pathogenesis, and management, Cancer and Metastasis Reviews, vol.23, issue.3/4, pp.3-4389, 2004.
DOI : 10.1023/B:CANC.0000031775.04618.30

S. Mohan and A. Chang, Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations, Current Dermatology Reports, vol.126, issue.12, pp.40-45, 2014.
DOI : 10.1007/s13671-014-0069-y

A. Rubin, E. Chen, and D. Ratner, Basal-Cell Carcinoma, New England Journal of Medicine, vol.353, issue.21, pp.2262-2271, 2005.
DOI : 10.1056/NEJMra044151

P. Ting, R. Kasper, and J. Arlette, Metastatic Basal Cell Carcinoma: Report of Two Cases and Literature Review, Journal of Cutaneous Medicine and Surgery, vol.34, issue.1, pp.10-15, 2005.
DOI : 10.1007/s10227-005-0027-1

M. Dandurand, T. Petit, and P. Martel, Management of basal cell carcinoma in adults Clinical practice guidelines, Eur J Dermatol, vol.16, issue.4, pp.394-401, 2006.

G. Staub, M. Revol, and P. May, Marges d???ex??r??se chirurgicale et taux de r??cidive des carcinomes cutan??s, Annales de Chirurgie Plastique Esth??tique, vol.53, issue.5, pp.389-98, 2008.
DOI : 10.1016/j.anplas.2007.07.015

K. Peris, S. Tambone, and D. Kostaki, Treatments of advanced basal cell carcinoma: a review of the literature, G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr, 2014.

K. Mosterd, G. Krekels, and F. Nieman, Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up, The Lancet Oncology, vol.9, issue.12, pp.1149-56, 2008.
DOI : 10.1016/S1470-2045(08)70260-2

J. Petit, M. Avril, and A. Margulis, Evaluation of Cosmetic Results of a Randomized Trial Comparing Surgery and Radiotherapy in the Treatment of Basal Cell Carcinoma of the Face, Plastic & Reconstructive Surgery, vol.105, issue.7, pp.2544-51, 2000.
DOI : 10.1097/00006534-200006000-00039

V. Huguier, E. Wierzbicka-hainaut, and J. Fray, Syndrome de Gorlin??: la phototh??rapie dynamique, technique compl??mentaire du traitement chirurgical, Annales de Chirurgie Plastique Esth??tique, vol.57, issue.2, pp.173-179, 2012.
DOI : 10.1016/j.anplas.2011.07.002

C. Berking, A. Hauschild, and O. Kölbl, Basal cell carcinoma-treatments for the commonest skin cancer, Dtsch Ärztebl Int, vol.111, issue.22, pp.389-95, 2014.

U. Wollina, Update of cetuximab for non-melanoma skin cancer, Expert Opinion on Biological Therapy, vol.35, issue.5, pp.271-277, 2014.
DOI : 10.1007/s00066-013-0378-2

M. Varjosalo and J. Taipale, Hedgehog: functions and mechanisms, Genes & Development, vol.22, issue.18, pp.2454-72, 2008.
DOI : 10.1101/gad.1693608

P. Ingham, Hedgehog signalling, Current Biology, vol.18, issue.6, pp.238-279, 2008.
DOI : 10.1016/j.cub.2008.01.050

S. Eaton, Multiple roles for lipids in the Hedgehog signalling pathway, Nature Reviews Molecular Cell Biology, vol.133, issue.9, pp.437-482, 2008.
DOI : 10.1038/nrm2414

C. Zhang, E. Williams, and Y. Guo, Extensive phosphorylation of Smoothened in Hedgehog pathway activation, Proceedings of the National Academy of Sciences, vol.101, issue.52, pp.17900-17907, 2004.
DOI : 10.1073/pnas.0408093101

Y. Chen and J. Jiang, Decoding the phosphorylation code in Hedgehog signal transduction, Cell Research, vol.21, issue.2, pp.186-200, 2013.
DOI : 10.1038/cr.2013.10

T. Østerlund and P. Kogerman, Hedgehog signalling: how to get from Smo to Ci and Gli, Trends in Cell Biology, vol.16, issue.4, pp.176-80, 2006.
DOI : 10.1016/j.tcb.2006.02.004

H. Roberg-larsen, M. Strand, and S. Krauss, Metabolites in vertebrate Hedgehog signaling, Biochemical and Biophysical Research Communications, vol.446, issue.3, pp.669-74, 2014.
DOI : 10.1016/j.bbrc.2014.01.087

R. Teperino, F. Aberger, and H. Esterbauer, Canonical and non-canonical Hedgehog signalling and the control of metabolism, Seminars in Cell & Developmental Biology, vol.33, pp.81-92, 2014.
DOI : 10.1016/j.semcdb.2014.05.007

D. Brennan, X. Chen, and L. Cheng, Noncanonical Hedgehog Signaling, Vitam Horm, vol.88, pp.55-72, 2012.
DOI : 10.1016/B978-0-12-394622-5.00003-1

L. Shevde and R. Samant, Nonclassical hedgehog-gli signaling and its clinical implications, International Journal of Cancer, vol.16, issue.1, pp.1-6, 2014.
DOI : 10.1002/ijc.28424

M. Ramalho-santos, D. Melton, and A. Mcmahon, Hedgehog signals regulate multiple aspects of gastrointestinal development, Dev Camb Engl, vol.127, issue.12, pp.2763-72, 2000.

E. Agha, E. , A. Alam, D. Carraro, and G. , Characterization of a Novel Fibroblast Growth Factor 10 (Fgf10) Knock-In Mouse Line to Target Mesenchymal Progenitors during Embryonic Development, PLoS ONE, vol.7, issue.6, p.38452, 2012.
DOI : 10.1371/journal.pone.0038452.s001

H. Miura, H. Kato, and Y. Kusakabe, Shh Signaling and Regulatory Gene Expression in Mouse Taste Buds, Chemical Senses, vol.30, issue.Supplement 1, pp.50-51, 2005.
DOI : 10.1093/chemse/bjh108

A. Mcmahon, P. Ingham, and C. Tabin, 1 Developmental roles and clinical significance of Hedgehog signaling, Curr Top Dev Biol, vol.53, pp.1-114, 2003.
DOI : 10.1016/S0070-2153(03)53002-2

D. Mehta, N. Raval, and H. Patadiya, Gorlin-Goltz syndrome, Annals of Medical and Health Sciences Research, vol.4, issue.2, pp.279-82, 2014.
DOI : 10.4103/2141-9248.129064

E. Roessler, Y. Du, and J. Mullor, Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features, Proceedings of the National Academy of Sciences, vol.100, issue.23, pp.13424-13433, 2003.
DOI : 10.1073/pnas.2235734100

D. Amakye, Z. Jagani, and M. Dorsch, Unraveling the therapeutic potential of the Hedgehog pathway in cancer, Nature Medicine, vol.31, issue.11, pp.1410-1432, 2013.
DOI : 10.1002/mpo.10121

S. Scales and F. De-sauvage, Mechanisms of Hedgehog pathway activation in cancer and implications for therapy, Trends in Pharmacological Sciences, vol.30, issue.6, pp.303-315, 2009.
DOI : 10.1016/j.tips.2009.03.007

C. Shelton and A. Gilmartin, Novel receptor antagonists for cancer therapy: hedgehog pathway inhibitors, Drug Discovery Today: Therapeutic Strategies, vol.6, issue.2, pp.63-72, 2009.
DOI : 10.1016/j.ddstr.2009.07.001

E. Epstein, Basal cell carcinomas: attack of the hedgehog, Nature Reviews Cancer, vol.14, issue.10, pp.743-54, 2008.
DOI : 10.1001/jama.294.6.681

W. Binns, L. James, and R. Keeler, Effects of teratogenic agents in range plants, Cancer Res, vol.28, issue.11, pp.2323-2329, 1968.

J. Chen, J. Taipale, and M. Cooper, Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened, Genes & Development, vol.16, issue.21, pp.2743-2751, 2002.
DOI : 10.1101/gad.1025302

P. Heretsch, L. Tzagkaroulaki, and A. Giannis, Modulators of the hedgehog signaling pathway, Bioorganic & Medicinal Chemistry, vol.18, issue.18, pp.6613-6637, 2010.
DOI : 10.1016/j.bmc.2010.07.038

Y. Li, M. Maitah, and A. Ahmad, Targeting the Hedgehog signaling pathway for cancer therapy, Expert Opinion on Therapeutic Targets, vol.70, issue.1, pp.49-66, 2012.
DOI : 10.1371/journal.pbio.0040232

M. Ruat, L. Hoch, and H. Faure, Targeting of Smoothened for therapeutic gain, Trends in Pharmacological Sciences, vol.35, issue.5, pp.237-283, 2014.
DOI : 10.1016/j.tips.2014.03.002

URL : https://hal.archives-ouvertes.fr/hal-01055292

F. Cirrone and C. Harris, Vismodegib and the Hedgehog Pathway: A New Treatment for Basal Cell Carcinoma, Clinical Therapeutics, vol.34, issue.10, pp.2039-50, 2012.
DOI : 10.1016/j.clinthera.2012.08.011

A. Abidi, Hedgehog signaling pathway: A novel target for cancer therapy: Vismodegib, a promising therapeutic option in treatment of basal cell carcinomas, Indian Journal of Pharmacology, vol.46, issue.1, pp.3-12, 2014.
DOI : 10.4103/0253-7613.124884

S. Aditya and A. Rattan, Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma, Indian Dermatology Online Journal, vol.4, issue.4, pp.365-373, 2013.
DOI : 10.4103/2229-5178.120685

R. Graham, C. Hop, and M. Borin, Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects, British Journal of Clinical Pharmacology, vol.4, issue.1, pp.788-96, 2012.
DOI : 10.1111/j.1365-2125.2012.04281.x

R. Graham, B. Lum, and S. Cheeti, Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding, Clinical Cancer Research, vol.17, issue.8, pp.2512-2532, 2011.
DOI : 10.1158/1078-0432.CCR-10-2736

P. Lorusso, A. Jimeno, and G. Dy, Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors, Clinical Cancer Research, vol.17, issue.17, pp.5774-82, 2011.
DOI : 10.1158/1078-0432.CCR-11-0972

M. Sharma, T. Karrison, and B. Kell, Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients, Clinical Cancer Research, vol.19, issue.11, pp.3059-67, 2013.
DOI : 10.1158/1078-0432.CCR-12-3829

V. Hoff, D. Lorusso, P. Rudin, and C. , Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.361, issue.12, pp.1164-72, 2009.
DOI : 10.1056/NEJMoa0905360

A. Sekulic, M. Migden, and A. Oro, Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2171-2180, 2012.
DOI : 10.1056/NEJMoa1113713

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

J. Tang, J. Mackay-wiggan, and M. Aszterbaum, Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome, New England Journal of Medicine, vol.366, issue.23, pp.2180-2188, 2012.
DOI : 10.1056/NEJMoa1113538

J. Grob, R. Kunstfeld, and T. Jouary, Vismodegib (V), un inhibiteur de la voie Hedgehog (HPI), dans le carcinome basocellulaire avanc?? (CBCa)??: analyse interm??diaire de l?????tude STEVIE, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.12, p.394, 2013.
DOI : 10.1016/j.annder.2013.09.073

D. Vidal® and E. , Disponible sur: http, p.132555

H. Wong, J. Chen, and B. Chou, -(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor, Xenobiotica, vol.422, issue.11, pp.850-61, 2009.
DOI : 10.1593/neo.81264

P. Lorusso, S. Piha-paul, and M. Mita, Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug???drug interaction potential, Cancer Chemotherapy and Pharmacology, vol.276, issue.suppl 8, pp.193-202, 2013.
DOI : 10.1007/s00280-012-1996-6

C. Rudin, C. Hann, and J. Laterra, Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449, New England Journal of Medicine, vol.361, issue.12, pp.1173-1181, 2009.
DOI : 10.1056/NEJMoa0902903

R. Yauch, G. Dijkgraaf, and B. Alicke, Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma, Science, vol.326, issue.5952, pp.572-576, 2009.
DOI : 10.1126/science.1179386

G. Dijkgraaf, B. Alicke, and L. Weinmann, Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance, Cancer Research, vol.71, issue.2, pp.435-479, 2011.
DOI : 10.1158/0008-5472.CAN-10-2876

R. Meani, S. Lim, and A. Chang, Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449), Australasian Journal of Dermatology, vol.148, issue.3, pp.218-239, 2014.
DOI : 10.1111/ajd.12196

A. Chang and A. Oro, Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma, Archives of Dermatology, vol.148, issue.11, pp.1324-1329, 2012.
DOI : 10.1001/archdermatol.2012.2354

C. Metcalfe and F. De-sauvage, Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists, Cancer Research, vol.71, issue.15, pp.5057-61, 2011.
DOI : 10.1158/0008-5472.CAN-11-0923

T. Brinkhuizen, M. Reinders, and M. Van-geel, Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma, Journal of the American Academy of Dermatology, vol.71, issue.5, 2014.
DOI : 10.1016/j.jaad.2014.08.001

M. Kool, D. Jones, and N. Jäger, Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition, Cancer Cell, vol.25, issue.3, pp.393-405, 2014.
DOI : 10.1016/j.ccr.2014.02.004

K. Queiroz, C. Spek, and M. Peppelenbosch, Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors, Drug Resistance Updates, vol.15, issue.4, pp.211-233, 2012.
DOI : 10.1016/j.drup.2012.05.002

J. Kim, B. Aftab, and J. Tang, Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists, Cancer Cell, vol.23, issue.1, pp.23-34, 2013.
DOI : 10.1016/j.ccr.2012.11.017

T. Ishii, Y. Shimizu, and K. Nakashima, Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant, European Journal of Pharmacology, vol.723, pp.305-318, 2014.
DOI : 10.1016/j.ejphar.2013.11.014

S. Buonamici, J. Williams, and M. Morrissey, Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma, Science Translational Medicine, vol.2, issue.51
DOI : 10.1126/scitranslmed.3001599

A. Chang, J. Solomon, and J. Hainsworth, Expanded access study of patients with advanced basal??cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib, Journal of the American Academy of Dermatology, vol.70, issue.1, pp.60-69, 2014.
DOI : 10.1016/j.jaad.2013.09.012

O. Kane, G. Lyons, T. Mcdonald, and I. , Vismodegib in the treatment of advanced BCC, Ir Med J, vol.107, issue.7, pp.215-221, 2014.

D. Ventarola and D. Silverstein, Vismodegib-associated hepatotoxicity: A potential side effect detected in postmarketing surveillance, Journal of the American Academy of Dermatology, vol.71, issue.2, pp.397-405, 2014.
DOI : 10.1016/j.jaad.2014.04.023

M. Ally, S. Aasi, and A. Wysong, An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma, Journal of the American Academy of Dermatology, vol.71, issue.5, 2014.
DOI : 10.1016/j.jaad.2014.05.020

H. Liu, A. Ermilov, and M. Grachtchouk, Multiple Shh signaling centers participate in fungiform papilla and taste bud formation and maintenance, Developmental Biology, vol.382, issue.1, pp.82-97, 2013.
DOI : 10.1016/j.ydbio.2013.07.022

A. Piccioni, E. Gaetani, and M. Palladino, Sonic hedgehog gene therapy increases the ability of the dystrophic skeletal muscle to regenerate after injury, Gene Therapy, vol.126, issue.4
DOI : 10.1016/j.exger.2013.06.005

W. Woo, H. Zhen, and A. Oro, Shh maintains dermal papilla identity and hair morphogenesis via a Noggin-Shh regulatory loop, Genes & Development, vol.26, issue.11, pp.1235-1281, 2012.
DOI : 10.1101/gad.187401.112

C. Gaudy-marqueste, E. Archier, and S. Monestier, Nouvelle r??ponse d???un carcinome basocellulaire au vismodegib, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.12, p.448, 2013.
DOI : 10.1016/j.annder.2013.09.200

H. Gill, E. Moscato, and R. Silkiss, Indications and Limitations of Vismodegib for Basal Cell Carcinoma???Reply, JAMA Ophthalmology, vol.132, issue.7, p.906, 2014.
DOI : 10.1001/jamaophthalmol.2014.1805

R. Gathings, C. Orscheln, and W. Huang, Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin, Journal of the American Academy of Dermatology, vol.70, issue.4, pp.88-97, 2014.
DOI : 10.1016/j.jaad.2013.11.032

A. Kahana, F. Worden, and V. Elner, Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell Carcinoma, JAMA Ophthalmology, vol.131, issue.10, pp.1364-1370, 2013.
DOI : 10.1001/jamaophthalmol.2013.4430